Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Immunovia AB ( (SE:IMMNOV) ).
Immunovia’s laboratory in North Carolina has received accreditation from the College of American Pathologists (CAP), confirming its adherence to rigorous global standards for quality, accuracy, and patient safety in its PancreaSure testing process. This accreditation enhances Immunovia’s reputation for excellence in laboratory operations, potentially strengthening its position in the pancreatic cancer diagnostics industry and assuring stakeholders of its commitment to high-quality service.
More about Immunovia AB
Immunovia AB is a diagnostic company dedicated to improving survival rates for pancreatic cancer patients through early detection. The company focuses on developing and commercializing simple tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to make these tests available to high-risk individuals. The USA is the largest market for pancreatic cancer detection, with Immunovia estimating that 1.8 million high-risk individuals could benefit from annual surveillance testing.
YTD Price Performance: -17.92%
Average Trading Volume: 13,971,863
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK223M
See more data about IMMNOV stock on TipRanks’ Stock Analysis page.